|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005516,
umls-concept:C0019196,
umls-concept:C0030705,
umls-concept:C0205314,
umls-concept:C0229671,
umls-concept:C0239946,
umls-concept:C0441889,
umls-concept:C0679622,
umls-concept:C1419891,
umls-concept:C1609943,
umls-concept:C1954435
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2009-2-4
|
|
pubmed:abstractText |
Syndecan 1 (CD 138) is a cell surface proteoglycan shed by cells in several pathological conditions, including wound healing. The aim of this study was to test whether CD138 could serve as a non-invasive marker for detection of liver fibrosis and thereby reduce the need for liver biopsy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1478-3231
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
208-12
|
|
pubmed:meshHeading |
pubmed-meshheading:18694404-Adult,
pubmed-meshheading:18694404-Area Under Curve,
pubmed-meshheading:18694404-Biological Markers,
pubmed-meshheading:18694404-Biopsy,
pubmed-meshheading:18694404-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:18694404-Female,
pubmed-meshheading:18694404-France,
pubmed-meshheading:18694404-Hepatitis C,
pubmed-meshheading:18694404-Humans,
pubmed-meshheading:18694404-Israel,
pubmed-meshheading:18694404-Liver Cirrhosis,
pubmed-meshheading:18694404-Male,
pubmed-meshheading:18694404-Middle Aged,
pubmed-meshheading:18694404-Syndecan-1
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Syndecan 1 (CD138) serum levels: a novel biomarker in predicting liver fibrosis stage in patients with hepatitis C.
|
|
pubmed:affiliation |
Gastroenterology Institute and Liver Unit, Tel Aviv Sourasky Medical Center, Weizmann 6, Tel Aviv, Israel. isab@tasmc.health.gov.il
|
|
pubmed:publicationType |
Journal Article
|
